Effects of dual therapy with corticosteroids plus long acting β 2-agonists in asthma

Respiratory Medicine

Volumn 99, Issue 6, 2005, Pages 683-694

  Currie, Graeme P ^a   Lee, Daniel K C ^b   Wilson, Andrew M ^c  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b IPSWICH HOSPITAL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Asthma; Bronchial hyperresponsiveness; Budesonide; Eformoterol; Fluticasone; Inflammation; Leukotriene receptor antagonist; Long acting 2 agonist; Montelukast; Randomised controlled trial; Salmeterol; Seretide; Symbicort; Theophylline; Zafirlukast

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID RECEPTOR; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LONG ACTING DRUG; METHACHOLINE; MONTELUKAST; NITRIC OXIDE; PLACEBO; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE; ZAFIRLUKAST;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; INHALER; LOW DRUG DOSE; LUNG FUNCTION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

EID: 18244408226     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.11.008     Document Type: Article

References (70)

1. G.P. Currie C.M. Jackson B.J. Lipworth Does bronchial hyperresponsiveness in asthma matter? J Asthma 41 2004 247-258
2. P. Lange J. Parner J. Vestbo P. Schnohr G. Jensen A 15-year follow-up study of ventilatory function in adults with asthma N Engl J Med 339 1998 1194-1200
3. P. Lange C.S. Ulrik J. Vestbo Mortality in adults with self-reported asthma. Copenhagen City Heart Study Group Lancet 347 1996 1285-1289
4. E. Huovinen J. Kaprio E. Vesterinen M. Koskenvuo Mortality of adults with asthma: A prospective cohort study Thorax 52 1997 49-54
5. W. Busse J. Elias D. Sheppard S. Banks-Schlegel Airway remodeling and repair Am J Respir Crit Care Med 160 1999 1035-1042
6. British guideline on the management of asthma Thorax 58 Suppl 1 2003 i1-i94
7. P.J. Barnes S. Pedersen W.W. Busse Efficacy and safety of inhaled corticosteroids. New developments Am J Respir Crit Care Med 157 1998 S1-S53
8. D. Olivieri A. Chetta M. Del Donno et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A placebo-controlled study Am J Respir Crit Care Med 155 1997 1864-1871
9. C.J. Trigg N.D. Manolitsas J. Wang et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma Am J Respir Crit Care Med 150 1994 17-22
10. S. Holt A. Suder M. Weatherall S. Cheng P. Shirtcliffe R. Beasley Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis BMJ 323 2001 253-256
11. G.P. Currie S.J. Fowler B.J. Lipworth Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: A meta-analysis Ann Allergy Asthma Immunol 90 2003 194-198
12. D.K.C. Lee C.E. Bates G.P. Currie L.M. Cowan L.C. Mcfarlane B.J. Lipworth Effect of high dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatics with severely impaired lung function Chest 93 2004 253-258
13. M.H. Brutsche I.C. Brutsche M. Munawar et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study Lancet 356 2000 556-561
14. B.J. Lipworth Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis Arch Int Med 159 1999 941-955
15. B.J. Lipworth A.M. Wilson Dose-response to inhaled corticosteroids: benefits and risks Sem Respir Crit Care Med 19 1998 625-646
16. G.P. Currie C.M. Jackson S.A. Ogston B.J. Lipworth Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids QJM 96 2003 435-440
17. A.T. Nials D.I. Ball P.R. Butchers et al. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol Eur J Pharmacol 251 1994 127-135
18. L.K. Chong E. Cooper C.J. Vardey P.T. Peachell Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms Br J Pharmacol 123 1998 1009-1015
19. I. Erjefalt C.G. Persson Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways Am Rev Respir Dis 144 1991 788-791
20. P.B. Bolton P. Lefevre D.M. McDonald Salmeterol reduces early and late-phase plasma leakage and leukocyte adhesion in rat airways Am J Respir Crit Care Med 155 1997 1428-1435
21. G.M. Verleden M.G. Belvisi K.F. Rabe M. Miura P.J. Barnes Beta 2-adrenoceptor agonists inhibit NANC neural bronchoconstrictor responses in vitro J Appl Physiol 74 1993 1195-1199
22. H.J. Van Der Woude R. Aalbers Long-acting beta(2)-agonists: Comparative pharmacology and clinical outcomes Am J Respir Med 1 2002 55-74
23. G.P. Anderson A. Linden K.F. Rabe Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7 1994 569-578
24. M. Palmqvist T. Ibsen A. Mellen J. Lotvall Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients Am J Respir Crit Care Med 160 1999 244-249
25. A.E. Tattersfield C.G. Lofdahl D.S. Postma et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: A randomised trial Lancet 357 2001 257-261
26. J.A. Roberts P. Bradding K.M. Britten et al. The long-acting beta2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma Eur Respir J 14 1999 275-282
27. P.V. Gardiner C. Ward H. Booth A. Allison D.J. Hendrick E.H. Walters Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics Am J Respir Crit Care Med 150 1994 1006-1011
28. W.J. Calhoun K.L. Hinton J.J. Kratzenberg The effect of salmeterol on markers of airway inflammation following segmental allergen challenge Am J Respir Crit Care Med 163 2001 881-886
29. S.C. Lazarus H.A. Boushey J.V. Fahy et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial JAMA 285 2001 2583-2593
30. R.F. Lemanske Jr C.A. Sorkness E.A. Mauger et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial JAMA 285 2001 2594-2603
31. I. Aziz K.S. Tan I.P. Hall M.M. Devlin B.J. Lipworth Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol Eur Respir J 12 1998 580-584
32. L. Ramage B.J. Lipworth C.G. Ingram I.A. Cree D.P. Dhillon Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol Respir Med 88 1994 363-368
33. B.J. Lipworth I. Aziz A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol J Allergy Clin Immunol 103 1999 88-92
34. P.G. Gibson H. Powell Written action plans for asthma: An evidence-based review of the key components Thorax 59 2004 94-99
35. R. Aalbers V. Backer T.T. Kava et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma Curr Med Res Opin 20 2004 225-240
36. R.A. McIvor E. Pizzichini M.O. Turner P. Hussack F.E. Hargreave M.R. Sears Potential masking effects of salmeterol on airway inflammation in asthma Am J Respir Crit Care Med 158 1998 924-930
37. J.C. Kips B.J. O'Connor M.D. Inman K. Svensson R.A. Pauwels P.M. O'Byrne A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma Am J Respir Crit Care Med 161 2000 996-1001
38. M.R. Sears D.R. Taylor C.G. Print et al. Regular inhaled beta-agonist treatment in bronchial asthma Lancet 336 1990 1391-1396
39. J.M. Drazen E. Israel H.A. Boushey et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network N Engl J Med 335 1996 841-847
40. S.M. Dennis S.J. Sharp M.R. Vickers et al. Regular inhaled salbutamol and asthma control: The TRUST randomised trial. Therapy Working Group of the National Asthma Task force and the MRC General Practce Research Framework Lancet 355 2000 1675-1679
41. S. Shrewsbury S. Pyke M. Britton Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) BMJ 320 2000 1368-1373
42. P.M. O'Byrne P.J. Barnes R. Rodriguez-Roisin et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392-1397
43. D. Price D. Dutchman A. Mawson B. Bodalia S. Duggan P. Todd Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose Thorax 57 2002 791-798
44. A.M. Strand A. Luckow Initiation of maintenance treatment of persistent asthma: Salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone Respir Med 98 2004 1008-1015
45. A.P. Greening P.W. Ind M. Northfield G. Shaw Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group Lancet 344 1994 219-224
46. A. Woolcock B. Lundback N. Ringdal L.A. Jacques Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Respir Crit Care Med 153 1996 1481-1488
47. R.A. Pauwels C.G. Lofdahl D.S. Postma et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405-1411
48. M. Roth P.R. Johnson J.J. Rudiger et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling Lancet 360 2002 1293-1299
49. O. Eickelberg M. Roth R. Lorx et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells J Biol Chem 274 1999 1005-1010
50. B.E. Orsida C. Ward X. Li et al. Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma Am J Respir Crit Care Med 164 2001 117-121
51. I.M. Adcock K. Maneechotesuwan O. Usmani Molecular interactions between glucocorticoids and long-acting beta2-agonists J Allergy Clin Immunol 110 2002 S261-S268
52. J.C. Mak T. Hisada M. Salmon P.J. Barnes K.F. Chung Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases Br J Pharmacol 135 2002 987-996
53. S.E. Wenzel G.L. Larsen K. Johnston N.F. Voelkel J.Y. Westcott Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge Am Rev Respir Dis 142 1990 112-119
54. I.D. Pavord R. Ward G. Woltmann A.J. Wardlaw J.R. Sheller R. Dworski Induced sputum eicosanoid concentrations in asthma Am J Respir Crit Care Med 160 1999 1905-1909
55. S.E. Wenzel S.J. Szefler D.Y. Leung S.I. Sloan M.D. Rex R.J. Martin Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids Am J Respir Crit Care Med 156 1997 737-743
56. R. Dworski G.A. Fitzgerald J.A. Oates J.R. Sheller Effect of oral prednisone on airway inflammatory mediators in atopic asthma Am J Respir Crit Care Med 149 1994 953-959
57. K.M. O'Shaughnessy R. Wellings B. Gillies R.W. Fuller Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion Am Rev Respir Dis 147 1993 1472-1476
58. G.P. Currie B.J. Lipworth Bronchoprotective Effects of Leukotriene Receptor Antagonists in Asthma: A Meta-analysis Chest 122 2002 146-150
59. J.E. Fish E. Israel J.J. Murray et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy Chest 120 2001 423-430
60. H.S. Nelson R.A. Nathan C. Kalberg S.W. Yancey K.A. Rickard Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids Med Gen Med 3 2001 3
61. L. Bjermer H. Bisgaard J. Bousquet et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial BMJ 327 2003 891
62. G.P. Currie C.E. Bates D.K. Lee C.M. Jackson B.J. Lipworth Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients Eur J Clin Pharmacol 59 2003 11-15
63. G.P. Currie D.K. Lee K. Haggart C.E. Bates B.J. Lipworth Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma Am J Respir Crit Care Med 167 2003 1232-1238
64. J. Ilowite R. Webb B. Friedman et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: A randomized, double-blind, multicenter study Ann Allergy Asthma Immunol 92 2004 641-648
65. L.P. Boulet H. Turcotte A. Brochu Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission Chest 105 1994 1024-1031
66. A.M. Vignola P. Chanez A.M. Campbell et al. Airway inflammation in mild intermittent and in persistent asthma Am J Respir Crit Care Med 157 1998 403-409
67. B. Davies G. Brooks M. Devoy The efficacy and safety of salmeterol compared to theophylline: Meta-analysis of nine controlled studies Respir Med 92 1998 256-263
68. C. Ward M. Pais R. Bish et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma Thorax 57 2002 309-316
69. H.K. Reddel C.R. Jenkins G.B. Marks et al. Optimal asthma control, starting with high doses of inhaled budesonide Eur Respir J 16 2000 226-235
70. R.H. Green C.E. Brightling S. McKenna et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial Lancet 360 2002 1715-1721